Taken from DeciBio’s 2019 Liquid Biopsy Market Report, the Investor Toolkit discusses tips for overcoming unique challenges faced by investors who participate in or have an interest in the liquid biopsy space, including:

• Questions to ask before investing
• Red flags to look out for
• Where to find investment opportunities
• Expected timeline on returns

Over $4B has been invested over the past three years, with GRAIL accounting for nearly 30% of that funding. With the market maturing and over 80 companies still competing with liquid biopsy offerings, it is paramount for investors to be able to cut through the noise and identify the winners.

Fill out the form below to download the Liquid Biopsy Market Report – Stakeholder Toolkit.

‍